A review of the diagnosis, pharmacologie treatment, and economic aspects of anxiety disorders

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 3, Issue 3, 2001, Pages 110-117

  Arikian, Steven R ^a,b   German, Jack M ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2942645637     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v03n0302     Document Type: Article

References (53)

1. DuPont RL, Rice DP, Miller LS, et al. Economic cost of anxiety disorders.Anxiety 1996;2:167-172.
2. Regier DA, Narrow WE, Rae DS, et al. The de facto US mental and addielive disorders service system: epidemiologic catchment area prospective 1 -year prevalence rates of disorders and services. Arch Gen Psychiarty 1993;50:85-94.
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month preva-lence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
4. American Psychiatric Association. Anxiety algorithm. In: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Primary Care Version: DSM-IV-PC. Washington, DC: American Psychiatric Association; 1995:47-63
5. Hales RE, Hilty D A, Wise MG. A treatment algorithm for the management of anxiety in primary care practice. J Clin Psychiatry 1997;58(suppl 3): 76-80
6. Burke WJ, Folks DG, McNeilly DP. Effective use of anxiolytics in older adults. Clin Geriatr Med 1998; 14:47-65
7. Martin LM, Fleming KC, Evans JM. Recognition and management of anxiety and depression in elderly patients. Mayo Clin Proc 1995;70: 999-1006
8. Schweizer E, Rickeis K. Strategies for treatment of generalized anxiety in the primary care setting. J Clin Psychiatry 1997;58(suppl 3):27-33
9. Bridges KW, Goldberg DP. Somatic presentation of DSM-III psychiatric disorders in primary care. J Psychosom Res 1985;29:563-569
10. Kroenke K, Spitzer RL, Williams JBW, et al. Physical symptoms in primary care: predictors of psychiatric disorders and functional impairment. ArchFamMed 1994;3:774-779
11. Beitman BD, Basha I, Flaker G, et al. Atypical or nonanginal chest pain: panic disorder or coronary artery disease? Arch Intern Med 1987; 147: 1548-1552
12. Schurman RA, Kramer PD, Mitchell JB. The hidden mental health network: treatment of mental illness by nonpsychiatrist physicians. Arch Gen Psychiatry 1985;42:89-94
13. Goldberg D, Bridges K, Duncan-Jones P et al. Detecting anxiety and depression in general medical settings. BMJ 1988;297:897-899
14. Baughman OL III. Rapid diagnosis and treatment of anxiety and depression in primary care: the somatizing patient. J Fam Pract 1994;39:373-378
15. Spitzer RL, Williams JBW, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRFME-MD 1000 Study. JAMA 1994;272:1749-1756
16. Zajecka J. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry 1997;58(suppl 3):9-13
17. Goldberg RJ. Diagnostic dilemmas presented by patients with anxiety and depression. Am J Med 1995;98:278-284
18. Nisenson LG, Pepper CM, Schwenk TL, et al. The nature and prevalence of anxiety disorders in primary care. Gen Hosp Psychiatry 1998;20:21-28
19. Brown C, Schulberg HC, Madonia MJ, et al. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychiatry 1996;153:1293-1300
20. Red Book 2000. Montvale, NJ: Medical Economics; 2000
21. Red Book Update 2000, vol 19, no. 6. Montvale, NJ: Medical Economics; 2000
22. Nutt DJ. The pharmacology of human anxiety. Pharmacol Ther 1990;47: 233-266
23. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monograph 1994;12(1):3-19
24. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
25. Liebowitz MR, Fryer AI, Gorman JM, et al. Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research. J Psychiatr Res 1988;22(suppl 1):7-31
26. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry 1996;57(suppl 10):51-58
27. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450
28. Jefferson JW. Antidepressants in panic disorder. J Clin Psychiatry 1997; 58(suppl 2):20-25
29. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371
30. Davidson JRT, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-535
31. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatinets with generalized ;: anxiety disorder: a 6-month randomized controlled trial. JAMA 2000; 283:3082-3088
32. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venjafaxine in nondepressed outpatients with generalized anxiety disorder Am J. Psychiatry 2000; 157:968-974
33. Allgulander C, Hackett D, Saunas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo study. Br J Psychiatry 2001; 179:15-22
34. Geacitoi TD Jr Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry 1995; 56:408-410
35. Papp LA, Sinba SS, Manez JM, et al. Low-dose venlafaxine treatment in panic disordetl- Psychiatry Bull 1997;34:207-209
36. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31 : 767-771
37. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with majo depresson. J Clin Psychiatry 1997; 58:393-398.
38. Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996;3 (3,suppl 2):37S-53S
39. Hedges DW, Reimherr FW, Strong RE, et al. Art open trial of nefazodone in adult patients with generalized anxiety disorder. Psygfiopharmacol Bull 1996;32:671-676
40. Fawcett J, Barkin RL. A meta-analysis of eight randomizeijlj-double-blind, controlled clinical trials of mirtazapine for the treatment :of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998;59: 123-127
41. Rice DP, Kelman S, Miller LS, et al. The Economic Costs of Alcohol and Drug Abuse and Mental Illness. Rockville, Md: US Dept Health Human Services; 1990. Report no. (ADM) 90-1694
42. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427-435
43. Katon W, Von Korff M, Lin E, et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry 1990;12:355-362
44. Katon W. Panic disorder: relationship to high medical utilization, unexplained physical symptoms, and medical costs. J Clin Psychiatry 1996; 57(suppl 10):11-18
45. Leon AC, Portera L, Weissman MM. The social costs of anxiety disorders. BrJ Psychiatry 1995;166(suppl 27):19-22
46. Souêtre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res 1994;38(suppl 1):151-160
47. Simon G, Ormel J, VonKorff M, et al. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152:352-357
48. Kessler RC, Price RH. Primary prevention of secondary disorders: a proposal and agenda. Am J Community Psychol 1993;21:607-633
49. Markowitz JS, Weissman MM, Ouellette R, et al. Quality of life in panic disorder. Arch Gen Psychiatry 1989;46:984-992
50. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173(suppl34):4-9
51. Prozac (fluoxetine hydrochloride). Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Co; 2001:1127-1132
52. Paxil (paroxetine). Physicians' Desk Reference. 55th ed. Montvale, NJ: Medical Economics Co; 2001:3114-3120
53. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexibledosage trial. J Clin Psychiatry 2001;62:350-357